POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (7.26.2021, 10:46am CEST, WHO):   India 39,742    Brazil 38,091    Russia 24,072    France 22,767    Turkey 12,381    Argentina 11,136    Columbia 11,064    Italy 5,138    Germany 1,387    Iran 27,146    Indonesia 38,679    Mexico 15,823    South Africa 12,056    Peru 1,765    The Netherlands 5,323    Chile 1,428    Iraq 9,147    Philippines 5,479    Bangladesh 11,291    Malaysia 17,045    Pakistan 2,819    Portugal 3,396    Japan 4,779    Israel 1,898    Jordan 1,061    Nepal 1,539    United Arab Emirates 1,528    Morocco 4,110    Saudi Arabia 1,194    Thailand 15,335    Greece 2,472    Belarus 1,061    Panama 1,096    Georgia 2,061    Guatemala 1,272    Cuba 8,853    Venezuela 1,022    Sri Lanka 1,666    Oman 4,912    Ireland 1,345    Myanmar 4,998    Libya 3,845    South Korea 1,318    Algeria 1,305    Mongolia 1,513    Mozambique 1,451    Vietnam 4,546    Zimbabwe 1,591    China 93    Singapore 125    New Zealand 3    Australia 162   

Hungary first in EU to approve Russian COVID-19 vaccine

Christian Fernsby |
Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the Sputnik V vaccine has been approved by the National Institute of Pharmacy and Nutrition of Hungary (OGYÉI).

Article continues below

Topics: HUNGARY    RUSSIA   

Thus Hungary has become the first country in the European Union to authorize the use of Sputnik V.

The vaccine was approved under the emergency use authorization procedure.

The approval is based on the results of the clinical trials of Sputnik V in Russia and a comprehensive assessment of the vaccine by experts in Hungary.

Sputnik V had been registered earlier under the same procedure in Algeria, Argentina, Bolivia, Serbia, Palestine, Venezuela, Paraguay and Turkmenistan.

The vaccine is also registered in Russia and Belarus.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said: "Hungary is the first EU country to realize all the advantages of Sputnik V vaccine and authorize its use.

This decision is very important as it demonstrates that the vaccine's safety and efficacy of over 90% are highly regarded by our partners in Hungary."

Sputnik V has a number of key advantages:

- Efficacy of Sputnik V is over 90%, with full protection against severe cases of COVID-19.

- The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

- Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

- The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

- Over 1.5mn people have already been vaccinated with Sputnik V.

- The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.

- The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan; the process to approve the vaccine in the EU has been initiated.

- There are no strong allergies caused by Sputnik V.

- The storage temperature of Sputnik V at +2 to +8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

- The price of Sputnik V is less than $10 per shot, making it affordable around the world.

What to read next

3-in-1 vaccine against traveler's diarrhea
U.S. starts coronavirus vaccine rollout
U.S. authorizes Moderna's coronavirus vaccine for emergency use